Safety, efficacy and pharmacokinetics of low-dose telitacicept in an elderly immunocompromised patient with systemic lupus erythematosus

Int J Rheum Dis. 2023 Jul;26(7):1399-1402. doi: 10.1111/1756-185X.14613. Epub 2023 Feb 19.

Authors

Xin Guan¹, Zerui Zhao², Guangtao Xia¹, Miaomiao Xin¹, Qingrui Yang¹, Hongling Sun¹, Min Fu¹

Affiliations

¹ Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University (Shandong Provincial Hospital), Jinan, China.
² Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Shandong University, Jinan, China.

PMID: 36807504
DOI: 10.1111/1756-185X.14613

No abstract available

Publication types

Letter

MeSH terms

Aged
Humans
Immunocompromised Host
Immunosuppressive Agents / adverse effects
Lupus Erythematosus, Systemic* / complications
Lupus Erythematosus, Systemic* / diagnosis
Lupus Erythematosus, Systemic* / drug therapy

Substances

telitacicept
Immunosuppressive Agents

Grants and funding

82001744/National Natural Science Foundation of China